Focal Treatments for Localized Prostate Cancer
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and medical necessity determinations for focal ablative therapies used to treat localized prostate cancer for Blue Cross Blue Shield - Rhode Island members, distinguishing Medicare Advantage and commercial products.
No material clinical or coverage changes in this revision.
Coverage Determinations and Criteria
Coverage determination
Applies to Medicare Advantage plans per policy statement.
Applies to commercial products per policy statement.
General medical necessity conclusion
Coverage stance and clinical conclusions from the evidence review
Supported by systematic reviews and observational studies with short follow-up and small sample sizes (chunk 18).
For Medicare Advantage, the policy states that use of any focal therapy modality to treat localized prostate cancer is not covered because the evidence is insufficient to determine effects on health outcomes. For Commercial Products, the policy concludes that use of any focal therapy modality to treat localized prostate cancer is not medically necessary for the same reason. These determinations apply to all focal ablative approaches discussed in the policy (for example, focal laser ablation, HIFU, cryoablation, RFA, photodynamic therapy, magnetic nanoparticle ablation, and irreversible electroporation) and reflect the absence of adequate prospective comparative evidence and standardized lesion selection methods.
The following procedure codes are identified as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products: 0655T, 0739T, and 55880. Each code corresponds to a specific focal prostate ablation technique as described in the coding section of the policy.
For Commercial Products, the policy specifically states that the use of any focal therapy modality to treat patients with localized prostate cancer is not medically necessary due to insufficient evidence to establish improved health outcomes.
As noted in the coding guidance, use of codes 0655T, 0739T, and 55880 is considered not covered for Medicare Advantage and not medically necessary for Commercial Products. When services addressed by this policy lack an assigned CPT code, report the service with 55899 (Unlisted procedure, male genital system) as indicated.
Coding and Billing Codes
| No codes listed |
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation |
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance |
| 55899 | Unlisted procedure, male genital system |
Provider Requirements, Billing Guidance, and Denial Risks
Prior authorization: Not applicable — verify member benefits
Prior authorization does not apply under this policy; however, benefits and prior authorization rules may vary by group or contract. Providers must verify the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine applicable prior authorization requirements for the patient.
Coverage and coding note: listed codes not covered; use 55899 for unlisted services
The policy identifies specific focal prostate ablation codes as not covered/not medically necessary and notes that services without assigned CPT codes must be reported using the unlisted procedure code 55899.
Check contract for step requirements
Benefits, coverage rules, and any step-therapy requirements may differ by contract. Providers must check the member's specific contract documents for any step requirements before proceeding.
Document clinical rationale and lesion targeting when considering focal therapy
If a focal prostate procedure is being considered or performed, document clinical rationale, intended target lesions, and why alternative standard treatments are not appropriate given that focal therapy techniques and outcomes are not standardized.
- Describe which lesion(s) (e.g., index lesion) are targeted and the method of localization/guidance used.
- Explain patient-specific reasons for choosing focal therapy over standard options (surgery, radiotherapy, active surveillance).
Evidence documentation: note heterogeneity and lack of prospective comparative studies
Evidence for focal therapies is heterogeneous and lacks prospective comparative trials; providers should include documentation that acknowledges evidence gaps and the absence of high-quality comparative data when submitting records for review.
- Note that no prospective, comparative evidence was found for most focal techniques versus standard treatments.
- State that methods for lesion selection and standardization are not established and that outcomes reporting is inconsistent.
Coding for unlisted procedures: report with 55899
When a focal prostate procedure performed has no assigned CPT code, report the service with unlisted procedure code 55899 (Unlisted procedure, male genital system) as specified in the policy.
Coverage denial risk: focal therapies for localized prostate cancer
Use of any focal therapy modality to treat localized prostate cancer is not covered for Medicare Advantage plans and is considered not medically necessary for commercial products; claims for focal therapies may therefore be denied.
Denial triggers: specific CPT/HCPCS codes (0655T, 0739T, 55880)
Claims listing specific focal therapy procedure codes 0655T, 0739T, or 55880 will be not covered for Medicare Advantage plans and considered not medically necessary for commercial products; submission of these codes may result in denial.
Clinical Background and Scope
Focal treatment for localized prostate cancer is intended to ablate the index or other identified cancerous lesion(s) to reduce tumor burden while preserving urinary, sexual, and rectal function compared with whole-gland therapies. Multiple energy-delivery modalities (for example, focal laser ablation, HIFU, cryoablation, radiofrequency ablation, photodynamic therapy, and irreversible electroporation) are described, but methods for lesion selection, targeting, and follow-up are not standardized. The evidence base is heterogeneous, consists largely of small observational studies with short follow-up, and lacks prospective comparative trials demonstrating improved net health outcomes; therefore, the policy does not support coverage of focal therapies outside investigational settings.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.